vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and Weatherford International plc (WFRD). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.2B, roughly 1.4× Weatherford International plc). Edwards Lifesciences runs the higher net margin — 23.1% vs 9.5%, a 13.6% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -8.3%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -9.5%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Weatherford International plc is an American multinational oilfield service company, headquartered in the US and operating in 75 countries globally across the oil and natural gas producing regions. The company provides technical equipment and services used for drilling, evaluation, completion, production, and intervention on gas and oil wells.

EW vs WFRD — Head-to-Head

Bigger by revenue
EW
EW
1.4× larger
EW
$1.6B
$1.2B
WFRD
Growing faster (revenue YoY)
EW
EW
+25.0% gap
EW
16.7%
-8.3%
WFRD
Higher net margin
EW
EW
13.6% more per $
EW
23.1%
9.5%
WFRD
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-9.5%
WFRD

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EW
EW
WFRD
WFRD
Revenue
$1.6B
$1.2B
Net Profit
$380.7M
$109.0M
Gross Margin
78.0%
Operating Margin
1.8%
10.7%
Net Margin
23.1%
9.5%
Revenue YoY
16.7%
-8.3%
Net Profit YoY
6.8%
42.1%
EPS (diluted)
$0.66
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
WFRD
WFRD
Q1 26
$1.6B
$1.2B
Q4 25
$1.6B
$1.3B
Q3 25
$1.6B
$1.2B
Q2 25
$1.5B
$1.2B
Q1 25
$1.4B
$1.2B
Q4 24
$1.4B
$1.3B
Q3 24
$1.4B
$1.4B
Q2 24
$1.4B
$1.4B
Net Profit
EW
EW
WFRD
WFRD
Q1 26
$380.7M
$109.0M
Q4 25
$91.2M
$138.0M
Q3 25
$291.1M
$81.0M
Q2 25
$333.2M
$136.0M
Q1 25
$358.0M
$76.0M
Q4 24
$385.6M
$112.0M
Q3 24
$3.1B
$157.0M
Q2 24
$366.3M
$125.0M
Gross Margin
EW
EW
WFRD
WFRD
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
EW
EW
WFRD
WFRD
Q1 26
1.8%
10.7%
Q4 25
9.6%
15.4%
Q3 25
19.8%
14.4%
Q2 25
26.8%
19.7%
Q1 25
27.9%
11.9%
Q4 24
22.6%
14.8%
Q3 24
25.9%
17.2%
Q2 24
26.8%
18.8%
Net Margin
EW
EW
WFRD
WFRD
Q1 26
23.1%
9.5%
Q4 25
5.8%
10.7%
Q3 25
18.7%
6.6%
Q2 25
21.7%
11.3%
Q1 25
25.3%
6.4%
Q4 24
27.8%
8.4%
Q3 24
226.7%
11.1%
Q2 24
26.7%
8.9%
EPS (diluted)
EW
EW
WFRD
WFRD
Q1 26
$0.66
$1.49
Q4 25
$0.16
$1.91
Q3 25
$0.50
$1.12
Q2 25
$0.56
$1.87
Q1 25
$0.61
$1.03
Q4 24
$0.65
$1.53
Q3 24
$5.13
$2.06
Q2 24
$0.61
$1.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
WFRD
WFRD
Cash + ST InvestmentsLiquidity on hand
$1.0B
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.8B
Total Assets
Debt / EquityLower = less leverage
0.84×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
WFRD
WFRD
Q1 26
$1.0B
Q4 25
$4.2B
$987.0M
Q3 25
$3.8B
$967.0M
Q2 25
$4.1B
$943.0M
Q1 25
$3.9B
$873.0M
Q4 24
$4.0B
$916.0M
Q3 24
$4.4B
$920.0M
Q2 24
$2.0B
$862.0M
Total Debt
EW
EW
WFRD
WFRD
Q1 26
$1.5B
Q4 25
$1.5B
Q3 25
$1.5B
Q2 25
$1.6B
Q1 25
$1.6B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.6B
Stockholders' Equity
EW
EW
WFRD
WFRD
Q1 26
$1.8B
Q4 25
$10.3B
$1.7B
Q3 25
$10.2B
$1.6B
Q2 25
$10.5B
$1.5B
Q1 25
$10.1B
$1.4B
Q4 24
$10.0B
$1.3B
Q3 24
$9.5B
$1.3B
Q2 24
$7.4B
$1.2B
Total Assets
EW
EW
WFRD
WFRD
Q1 26
Q4 25
$13.7B
$5.2B
Q3 25
$13.3B
$5.3B
Q2 25
$13.5B
$5.1B
Q1 25
$13.0B
$5.1B
Q4 24
$13.1B
$5.2B
Q3 24
$13.0B
$5.2B
Q2 24
$10.1B
$5.1B
Debt / Equity
EW
EW
WFRD
WFRD
Q1 26
0.84×
Q4 25
0.86×
Q3 25
0.94×
Q2 25
1.04×
Q1 25
1.17×
Q4 24
1.26×
Q3 24
1.21×
Q2 24
1.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
WFRD
WFRD
Operating Cash FlowLast quarter
$136.0M
Free Cash FlowOCF − Capex
$85.0M
FCF MarginFCF / Revenue
7.4%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
1.25×
TTM Free Cash FlowTrailing 4 quarters
$470.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
WFRD
WFRD
Q1 26
$136.0M
Q4 25
$450.9M
$268.0M
Q3 25
$573.7M
$138.0M
Q2 25
$290.2M
$128.0M
Q1 25
$280.4M
$142.0M
Q4 24
$-127.5M
$249.0M
Q3 24
$351.8M
$262.0M
Q2 24
$371.5M
$150.0M
Free Cash Flow
EW
EW
WFRD
WFRD
Q1 26
$85.0M
Q4 25
$353.5M
$217.0M
Q3 25
$516.2M
$94.0M
Q2 25
$240.9M
$74.0M
Q1 25
$224.4M
$65.0M
Q4 24
$-177.3M
$149.0M
Q3 24
$299.9M
$184.0M
Q2 24
$286.1M
$88.0M
FCF Margin
EW
EW
WFRD
WFRD
Q1 26
7.4%
Q4 25
22.5%
16.8%
Q3 25
33.2%
7.6%
Q2 25
15.7%
6.1%
Q1 25
15.9%
5.4%
Q4 24
-12.8%
11.1%
Q3 24
22.1%
13.1%
Q2 24
20.9%
6.3%
Capex Intensity
EW
EW
WFRD
WFRD
Q1 26
4.7%
Q4 25
6.2%
4.0%
Q3 25
3.7%
3.6%
Q2 25
3.2%
4.5%
Q1 25
4.0%
6.5%
Q4 24
3.6%
7.5%
Q3 24
3.8%
5.5%
Q2 24
6.2%
4.4%
Cash Conversion
EW
EW
WFRD
WFRD
Q1 26
1.25×
Q4 25
4.94×
1.94×
Q3 25
1.97×
1.70×
Q2 25
0.87×
0.94×
Q1 25
0.78×
1.87×
Q4 24
-0.33×
2.22×
Q3 24
0.11×
1.67×
Q2 24
1.01×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

WFRD
WFRD

Middle East/North Africa/Asia$476.0M41%
Europe/Sub-Sahara Africa/Russia$233.0M20%
Latin America$223.0M19%
North America$220.0M19%

Related Comparisons